Sign In
Buy SNY
$43.75
-0.230 (-0.523%)
At Close: Jul 21, 2026
Sanofi (SNY), Regeneron Dupixent Gets CHMP Nod for Skin Disease
09:02am, Monday, 14'th Nov 2022
The CHMP recommends approval of Sanofi's (SNY) Dupixent for the treatment of prurigo nodularis, a chronic inflammatory skin disease.
Top 5 stories of the week: Meta layoffs, Sanofi's billion-dollar deal and Snowflake updates
08:00am, Saturday, 12'th Nov 2022
Meta's massive layoff announcement led our coverage this week, but on the other end of the spectrum, biotech company Sanofi announced a billion-dollar deal in AI drug discovery.
Sanofi (SNY), GSK Receive EU Approval for COVID-19 Vaccine
01:33pm, Friday, 11'th Nov 2022
Sanofi (SNY) and partner GSK's COVID-19 vaccine receives authorization in the European Union for use as a booster in adults aged 18 years and older.
Sanofi SA (SNY) Q3 2022 Earnings Call Transcript
03:40pm, Friday, 28'th Oct 2022
Sanofi SA (NASDAQ:SNY ) Q3 2022 Results Conference Call October 28, 2022 8:30 AM ET Company Participants Eva Schaefer-Jansen - Head, IR Paul Hudson - CEO Bill Sibold - EVP, Specialty Care; President,
Sanofi (SNY) Q3 Earnings Beat, Dupixent, Flu Jabs Push Sales
02:18pm, Friday, 28'th Oct 2022
Sanofi (SNY) beats third-quarter estimates for earnings and sales. Dupixent and flu vaccines drive sales growth.
Sanofi Jumps As Strong Third-Quarter Profit Leads To Guidance Boost
09:02am, Friday, 28'th Oct 2022
Sanofi stock jumped Friday after the company reported better-than-expected third-quarter profit, leading to a guidance boost. The post Sanofi Jumps As Strong Third-Quarter Profit Leads To Guidance Boo
Sanofi posts higher sales but $2.07 billion net profit misses forecasts
02:09am, Friday, 28'th Oct 2022
By Cecilia Butini
2 High-Yielding Dividend Stocks That Haven't Been This Cheap in Years
10:00am, Friday, 14'th Oct 2022
Is now the time to buy Sanofi and Intel?
Sanofi CEO on using AI to support drug trials
03:52pm, Tuesday, 11'th Oct 2022
Paul Hudson, CEO of Sanofi, joins 'Power Lunch' to discuss solutions-oriented approaches for the pharmaceutical industry, and implementing AI technology in clinical trials to improve the probability o
2 Top Healthcare Stocks to Buy Right Now
09:35am, Saturday, 08'th Oct 2022
Healthcare is about as sticky of a business model as you'll find.
7 Under-$50 Stocks to Buy to Tap Into a Hidden Bull Market
11:24am, Friday, 07'th Oct 2022
Although crimson seems to be the shade of the moment in the equities sector, by targeting under-$50 stocks to buy, astute and daring investors may be able to tap into a hidden bull market. How can thi
Sanofi (SNY) Relies on Dupixent and Vaccines to Drive Growth
10:32am, Tuesday, 04'th Oct 2022
Dupixent has become the key top-line driver for Sanofi (SNY). Sanofi possesses a leading vaccine portfolio, which has become the primary top-line driver.
Here's Why the Post-Pandemic World May Be Even Better for This Vaccine Maker
06:00am, Saturday, 01'st Oct 2022
Moderna's billion-dollar revenue may be just getting started.
BlackRock's DeSpirito: Brace For Stubborn Inflation
07:00am, Friday, 30'th Sep 2022
Inflation is easing, says a top thinker for BlackRock, the world's largest asset manager. But it's not falling to what Americans have grown used to.
Sanofi's (SNY) Dupixent Gets FDA Nod for Prurigo Nodularis
12:47pm, Thursday, 29'th Sep 2022
The FDA approves Sanofi (SNY) and its partner Regeneron's Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis.
